Wed, Sep 04, 2024
Conversation with Dr Lal Pathlabs' top management on business and sector outlook. How is the current demand trend? What is the growth outlook for the future? What is the plan regarding capacity expansion? Watch Anil Singhvi's conversation with Ved Goyal, Group CFO of Dr Lal Pathlabs.
More >
Mon, May 13, 2024
Dr Lal PathLabs share price today: Diagnostics company Dr Lal PathLabs rose as much as 8.18 per cent to the day's high of Rs 2,540 on NSE in morning deals.
Fri, May 10, 2024
Dr Lal PathLabs Q4 Results: New Delhi-headquartered Dr Lal PathLabs reported a 49 per cent year-on-year jump in consolidated net profit to Rs 84.5 crore for the March quarter. Its quarterly revenue grew 11.1 per cent to Rs 545.4 crore.
Tue, Dec 19, 2023
Stocks of diagnostic test providers such as Dr Lal Pathlabs and Thyrocare were in demand on Tuesday after the government issued guidelines in connection with a new variant of COVID-19 amid an uptick in cases in some parts of the country.
Fri, Nov 03, 2023
Dr Lal PathLabs (LALPATHLAB) shares continued to rise for a second straight session after the medical diagnostics company reported a strong set of quarterly numbers.
Thu, Nov 02, 2023
Dr Lal PathLabs Q2 Results: Dr Lal PathLabs said its consolidated net profit increased by 54 per cent to Rs 111 crore for the second quarter ended September 30, 2023.
Tue, Dec 13, 2022
Dr Lal PathLabs shares dropped sharply in Dec 13's trade amid reports that the Delhi government is set to provide 450 types of medical tests free of cost from Jan 1.
Why the sharp decline in Dr Lal PathLabs? Which decision of Delhi government has put pressure on the stock? Know the complete details from Kushal Gupta.
Wed, Nov 09, 2022
Indian service provider of diagnostics Dr Lal Pathlabs’ share fell more than 8% as company’s Profit After Tax (PAT) declined by 25% at Rs 72 crore as compared to Rs 96 crore in the corresponding quarter of the previous year
Dr Lal Pathlabs share price: On NSE, at closing, the stock traded in red at Rs 2,414 which was down by 8.05 per cent.
Wed, Apr 13, 2022
Zee Business Executive Editor Swati Khandelwal Jain spoke with Om Manchanda, CEO of Dr. Lal PathLabs in a special Tv show 'Corporate Radar'.
Tue, Apr 05, 2022
Given increasing health awareness post-Covid, a higher share of wellness, specialized, and home collection segments will continue to aid realizations, the brokerage said.
Thu, Feb 24, 2022
Dr Lal PathLabs (DLPL) and Coal India can give up to 87% return within a period of one year at current levels, as per Centrum Broking.
Thu, Dec 16, 2021
The pandemic sharply boosted revenue and operating profit margins of national-level diagnostic firms during first half of the year which may help them log out 2021-22 with around 55 per cent jump in topline growth and around 800 basis points increase in operating margins, says a report.
Fri, Oct 01, 2021
Dr. Arvind Lal, Executive Chairman, Dr. Lal PathLabs Ltd., talks about the present business scenario amid a decline in COVID-19 tests, patient volumes, pricing pressure, plans to improve revenue & profit per laboratory.
Wed, May 26, 2021
Om Prakash Manchanda, Managing Director, DR Lal Pathlabs Pvt Ltd, talks about the outlook for COVID-19 and non-COVID tests in FY22, current market share, footprints, investment target and margin among others during a candid chat with Zee Business Executive Editor Swati Khandelwal
Mon, May 24, 2021
Despite its strong quarter four results, the brokerage firms post a mixed sentiment for Dr Lal Pathlabs. The diagnostic company’s reported a jump of two and half times higher profit in the fourth quarter of the financial year 2020-2021 on Friday.
Wed, May 05, 2021
The Reserve Bank of India (RBI) Governor Shaktikanta Das on Wednesday announced a loan of Rs 50000 cr for the healthcare emergencies. Moreover, the banks have been asked to make a separate loan book for Covid. Commenting on this, Zee Business Managing Editor Anil Singhvi said that these loans facilities should be used by hospitals, pathology labs and medical equipment companies
Mon, Apr 12, 2021
While the stock markets plummeted on Monday, the Nifty Pharma index did better than most of its peers. Though it ended in the red, the fall was just under 0.3 per cent from the previous closing price.
Tue, Apr 06, 2021
Top Stocks to Buy - Infosys, Dr Lal Pathlabs, JSW Steel and Ramco Cement were among the top trending stocks on the BSE today. The stocks achieved their 52-week highs on Tuesday. Technical Analyst Nilesh Jain Assistant Vice President (AVP), Equity Research Technical and Derivatives at Centrum Broking gives an insight on what lies ahead for these stocks and recommends what to do with them
Thu, Dec 17, 2020
Testing has reduced now and you would have followed all newspaper reports that cases are going down. It definitely increased in the past as there was definitely a spike around 10-15 days ago but today it has come down. And, our expectation is that now the testing will also go down because there is a decline in the number of detected cases. Secondly, any day the vaccine can be launched and I think form the first week of January would probably be a better date. After that the testing will change, maybe the government will start antibody testing more, which is known as IGG antibody test.
Wed, Sep 23, 2020
Dr Arvind Lal, Executive Chairman, Dr Lal PathLabs, talks about the number of COVID-19 tests that are done, expansion plans, saliva-based test for COVID-19 and the volume of other tests that it conducts among others during an interview with Zee Business Executive Editor Swati Khandelwal
Thu, Aug 06, 2020
Dr Om Manchanda, Managing Director, Dr Lal Pathlabs Ltd, talks about the Q1FY21 results, the contribution of COVID-19 tests in the numbers, impact of COVID on the business, etc.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
